Immune Design Corp. (IMDZ)

Oncology Corporate Profile

Stock Performance

14.8700
-0.3100

HQ Location

1616 Eastlake Ave. E., Suite 310
Seattle, WA 98102

Company Description

Immune Design is a clinical-stage biotechnology company employing leading-edge technologies that target dendritic cells for a more precise immune response for the treatment of cancer and other chronic conditions. The company's clinical programs are the product of its two synergistic discovery platforms: DCVexTM, a novel lentiviral vector platform engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo, and GLAASTM, a TLR4-agonist platform that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces Th1 cytokines to enhance the immune response.

Website: http://www.immunedesign.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
LV 305 (+ atezolizumab)immunotherapySarcomaIIGenentech / Roche
LV 305 (+ pembrolizumab)immunotherapyMelanomaIMerck
ID-G100 (+ pembrolizumab)immunotherapyMelanomaIMerck
ID-G100synthetic Toll-like receptor 4 agonistMerkel cell carcinomaI
ID-G100 (+ pembrolizumab)immunotherapyNon-Hodgkin's Lymphoma (NHL)IMerck
ID-G305immunotherapyVarious cancer typesI
LV305immunotherapyVarious cancer typesI
LV 305 (+ pembrolizumab)immunotherapyNon-Hodgkin's Lymphoma (NHL)Merck

View additional information on product candidates here »

Source: http://www.immunedesign.com

Recent News Headlines

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 12:18 pm

5/17/2017 06:18 am

5/10/2017 06:18 am

5/10/2017 06:18 am

5/10/2017 06:18 am

5/10/2017 06:18 am

5/10/2017 06:18 am

4/7/2017 12:17 pm

4/7/2017 12:17 pm

4/7/2017 06:17 am